The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the U.S. Yancopoulos , M.D., In the U.S.

Government 52

Government Hospitals Virus Production 52

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). The Phase 3 portion of this trial continues in non-hospitalized patients. In total, 47% of participants were male and 53% were female. .

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

NOVEMBER 5, 2020

. “Last week, Regeneron achieved an important milestone in the fight against COVID-19 with prospective Phase 2/3 results showing REGN-COV2 significantly reduced virus levels and the need for further medical attention in non-hospitalized patients; we have shared these important data with regulatory authorities,” said Leonard S.

Production 52

Production FDA FDA Approval Trials 52

Agency IQ

NOVEMBER 3, 2023

The prebiotic may either feed the probiotic that it is packaged with, or it may feed another beneficial microbe that is intended to complement the activity of the probiotic. Additionally, dietary supplements can make “claims of general well-being and claims related to a nutrient deficiency disease.”

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

AUGUST 3, 2021

The company announced plans to submit donanemab for Alzheimer’s disease and tirzepatide for type 2 diabetes to regulatory authorities by the end of 2021. – Second-quarter 2021 earnings per share (EPS) decreased to $1.53 on a reported basis and increased to $1.87 on a non-GAAP basis. on a non-GAAP basis. 2)% EPS – Reported 1.53

Production 52

Production Marketing Research Government 52

The Pharma Data

NOVEMBER 20, 2020

Casirivimab and imdevimab are not authorized for use in patients who are hospitalized or require oxygen therapy due to COVID-19, or for people currently using chronic oxygen therapy because of an underlying comorbidity who require an increase in baseline oxygen flow rate due to COVID-19. . “The Yancopoulos, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

AUGUST 3, 2021

BLINCYTO ® (blinatumomab), our BiTE ® immunotherapy, sales increased 16% year-over-year for the second quarter, driven by 18% volume growth as we benefited from broader adoption in the community hospital setting. A Phase 2 study continues to enroll patients with chronic obstructive pulmonary disease. In the U.S., Tezepelumab.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

AUGUST 3, 2021

While disease progression is slower in patients with later-onset SMA, there are significant unmet needs. “We SMA is a rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene, resulting in the irreversible loss of motor neurons, affecting muscle functions, including breathing, swallowing and basic movement.

Clinical Trials 52

Clinical Trials Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 21, 2020

Casirivimab and imdevimab are not authorized for use in patients who are hospitalized or require oxygen therapy due to COVID-19, or for people currently using chronic oxygen therapy because of an underlying comorbidity who require an increase in baseline oxygen flow rate due to COVID-19. . Yancopoulos , M.D., Limitations of Authorized Use.

FDA 40

FDA Clinical Trials Hospitals Government 40

Codon

FEBRUARY 13, 2024

alone, according to the Centers for Disease Control and Prevention. Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Crucially, it could also make them easier to license as therapeutic agents. 4 But the same barriers still exist today.

Therapies 118

Therapies Virus DNA Clinical Trials 118

Codon

JULY 27, 2023

CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. There’s a TV show where a bunch of doctors are walking through a hospital corridor. They’re talking about a patient who has a rare genetic disease. ” Gene-edited poplar tree stems appear red. From Sulis D.B. in Science.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. There’s a TV show where a bunch of doctors are walking through a hospital corridor. They’re talking about a patient who has a rare genetic disease. ” Gene-edited poplar tree stems appear red. From Sulis D.B. in Science.

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

NOVEMBER 30, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. ages 18 and older.

Vaccine 52

Vaccine FDA Clinical Trials Disease 52

The Pharma Data

MAY 13, 2021

And I was rushed to hospital in the back of an ambulance… As paramedics desperately tried to keep me alive. So go ahead and choose your discounted package of HB5 right now…. And the answer is to simply click on one of the packages you see below right now…. Once you’ve selected your package…. money back guarantee.00.

Production 52

Production Packaging Doctors Research 52

Agency IQ

JUNE 16, 2023

See Asbestos Disease Awareness Organization v. Final Rule Stage Clean Water Act Section 401: Water Quality Certification 2040-AG12 August 2023 Clean Water Act (CWA) section 401 provides States and Tribes with a powerful tool to protect the quality of their waters from adverse impacts resulting from federally licensed or permitted projects.

Regulations 40

Regulations Compliance Production Science 40